Use of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Comorbid Diabetes Mellitus or Chronic Kidney Disease

BACKGROUND: Perceived risks of hyperkalemia and acute renal insufficiency may limit use of mineralocorticoid receptor antagonist (MRA) therapy in patients with heart failure, especially those with diabetes mellitus or chronic kidney disease. METHODS AND RESULTS: Using clinical registry data linked t...

Descripción completa

Detalles Bibliográficos
Autores principales: Cooper, Lauren B., Lippmann, Steven J., Greiner, Melissa A., Sharma, Abhinav, Kelly, Jacob P., Fonarow, Gregg C., Yancy, Clyde W., Heidenreich, Paul A., Hernandez, Adrian F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779000/
https://www.ncbi.nlm.nih.gov/pubmed/29275368
http://dx.doi.org/10.1161/JAHA.117.006540

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779000/
https://www.ncbi.nlm.nih.gov/pubmed/29275368
http://dx.doi.org/10.1161/JAHA.117.006540

Ejemplares similares